PHARMACEUTICAL IP

  • Offering
    • Evolve AI
      • Albert
        • Validity analysis
        • Albert Construe
      • Popper
      • Franklin
      • AI for Sequences
    • Fractional IP counsel
    • Services
      • AI guidance
      • Competitive intelligence
      • Deals
      • Due diligence
      • Freedom to operate
      • IP strategy and communication
      • Oppositions and appeals
      • Patent drafting
      • Patent prosecution
      • Trade secrets
    • Technologies
      • Pharmaceuticals
      • Biologics
      • Cell & gene therapy
      • AI drug discovery
    • Our clients
      • Biotech
      • CROs and CMOs
      • Established pharma
      • International IP counsel
      • Investors
      • Start-ups
      • Universities
  • Fractional IP counsel
    • Fractional IP counsel
    • What is fractional IP counsel?
    • Our clients
      • Biotech
      • CROs and CMOs
      • Established pharma
      • International IP counsel
      • Investors
      • Start-ups
      • Universities
  • Evolve AI
    • Albert
      • Validity analysis
      • Albert Construe
    • Popper
    • Franklin
    • AI for Sequences
  • Technologies
    • Pharmaceuticals
      • Dosing regimens
      • Formulations
      • Life cycle management
      • New indications
      • Platform technologies
    • Biologics
      • Antibodies
      • Antibody-drug conjugates (ADCs)
      • T cell engagers (TCEs)
    • Cell & gene therapy
      • CAR-T cell therapies
      • Gene therapies
      • In vivo CAR-T
      • Lipid nanoparticles (LNPs)
      • Macrophages (CAR-M)
      • mRNA therapeutics
      • Regenerative cell therapies
    • AI drug discovery
  • Insights
    • Articles
    • Pharma IP Toolkit
    • Evolve Guides
    • Events & Webinars
    • Subscribe
  • About us
    • Our team
    • Recognition
    • Join us
    • Contact us
  • Offering
    • Evolve AI
      • Albert
        • Validity analysis
        • Albert Construe
      • Popper
      • Franklin
      • AI for Sequences
    • Fractional IP counsel
    • Services
      • AI guidance
      • Competitive intelligence
      • Deals
      • Due diligence
      • Freedom to operate
      • IP strategy and communication
      • Oppositions and appeals
      • Patent drafting
      • Patent prosecution
      • Trade secrets
    • Technologies
      • Pharmaceuticals
      • Biologics
      • Cell & gene therapy
      • AI drug discovery
    • Our clients
      • Biotech
      • CROs and CMOs
      • Established pharma
      • International IP counsel
      • Investors
      • Start-ups
      • Universities
  • Fractional IP counsel
    • Fractional IP counsel
    • What is fractional IP counsel?
    • Our clients
      • Biotech
      • CROs and CMOs
      • Established pharma
      • International IP counsel
      • Investors
      • Start-ups
      • Universities
  • Evolve AI
    • Albert
      • Validity analysis
      • Albert Construe
    • Popper
    • Franklin
    • AI for Sequences
  • Technologies
    • Pharmaceuticals
      • Dosing regimens
      • Formulations
      • Life cycle management
      • New indications
      • Platform technologies
    • Biologics
      • Antibodies
      • Antibody-drug conjugates (ADCs)
      • T cell engagers (TCEs)
    • Cell & gene therapy
      • CAR-T cell therapies
      • Gene therapies
      • In vivo CAR-T
      • Lipid nanoparticles (LNPs)
      • Macrophages (CAR-M)
      • mRNA therapeutics
      • Regenerative cell therapies
    • AI drug discovery
  • Insights
    • Articles
    • Pharma IP Toolkit
    • Evolve Guides
    • Events & Webinars
    • Subscribe
  • About us
    • Our team
    • Recognition
    • Join us
    • Contact us
  • Offering
  • What is fractional IP counsel?
  • Evolve AI
  • Technologies
  • Insights
  • Our team
  • Offering
  • What is fractional IP counsel?
  • Evolve AI
  • Technologies
  • Insights
  • Our team

Are AI-generated materials legally privileged? United States v. Heppner

  • Technology: Patent law
  • 13th May 2026
Legal privilege ensures that you can share sensitive information with your lawyers without fear of it being used against you in court. This protection is critical in all fields of law. In patent law, without the assurance of secrecy, the ability of a patentee or a defendant to receive candid advice would be severely diminished.
Single cut gold stone glowing turquoise at its heart on dark blue, Evolve abstract article image

Originally posted on IPKat

Now, with the growing ubiquity of AI in the legal industry, much attention has been given to the recent case of United States v. Heppner. The court was asked whether communications about a legal case with a publicly available AI platform were protected by attorney-client privilege or the similar work product doctrine. The judge’s answer was a clear “no”. Other than the obvious (don’t put confidential information into public AI tools!), what lessons can we take from this about the safe use of AI in the patent industry?

Evolve AI

AI and legal privilege: United States v. Heppner

Last year, Mr Heppner was indicted on federal charges including securities fraud. Following a grand jury subpoena and learning he was a target, Heppner, acting on his own without instruction from legal counsel, used Claude to prepare documents outlining his defence strategies. When Mr Heppner was subsequently arrested in November, federal agents executed a search warrant and seized electronic devices from his home that contained approximately thirty-one of these AI-generated documents. Heppner and his counsel asserted privilege, but the government moved to review the materials.

Judge Rakoff ruled that the AI-generated materials were not protected by attorney-client privilege. In a written memorandum, the judge explained that the AI tool failed the standard three-part test for privilege. Firstly, there was no attorney-client relationship because an AI is not a licensed professional bound by fiduciary duties or subject to professional discipline. Interestingly, in a completely unrelated case, ChatGPT has just been sued for providing legal advice without a licence. Secondly, the court found that there was no confidentiality in place as the Anthropic privacy policy for Claude discloses that it collects user inputs, trains on user data, and may disclose data to third parties including government authorities. 

Finally, the judge noted that Mr Heppner did not communicate with Claude “for the purpose of obtaining legal advice”, e.g. under the direction of counsel. Interestingly, the judge observed that “[h]ad counsel directed Heppner to use Claude, Claude might arguably be said to have functioned in a manner akin to a highly trained professional who may act as a lawyer’s agent within the protection of the attorney-client privilege”. However, because the Claude platform includes a disclaimer stating it cannot provide formal legal advice, Mr Heppner could not be considered to be seeking legal advice. As the judge also noted, “when the Government asked Claude whether it could give legal advice, it responded that ‘I’m not a lawyer and can’t provide formal legal advice or recommendations’ and went on to recommend that a user ‘should consult with a qualified attorney who can properly assess your specific circumstances'”.

Given these three circumstances, it was clear to the judge that legal privilege did not apply. 

The limits of protection (Work product doctrine)

The judge’s reasoning on privilege noted that “some commentators have argued that whether Claude is an attorney is irrelevant because a user’s AI inputs, rather than being communications, are more akin to the use of other Internet-based software, such as cloud-based word processing applications”. However, that judge noted that “the use of such applications is not intrinsically privileged in any case”. This leads to a second protection in US law, the work product doctrine (WPD). The WPD serves as a complementary shield to legal privilege by protecting materials prepared in anticipation of litigation. In the context of patents, this includes documents such as infringement analyses or validity opinions created by or for patent attorneys. This doctrine ensures that an attorney can prepare a case thoroughly without the risk of their internal thoughts and strategies being handed over to the other side.

In the Heppner case, the court also rejected the application of the WPD. Judge Rakoff noted again that the documents were created by Heppner independently in coordination with Claude rather than at the direction or supervision of counsel. Furthermore, simply sharing non-privileged communications with an attorney after they are created did not retroactively convert them into privileged ones. The WPD, the judge emphasised, is to protect the mental processes of lawyers, and “generally does not shield from discovery documents that were not prepared by the attorneys themselves, or their agents”. 

Analysis

The existence or otherwise of legal privilege or protection under the work product doctrine can be critical to the outcome of patent litigation in the US, and in particular the awarding of treble damages. In the US, a court may increase damages up to three times the amount found or assessed in cases of wilful infringement, i.e. where it can be proved that the defendant knew about the patent and that they were infringing. 

However, it is important to understand the limitations of the applicability of the decision in Heppner. Notably, the court did not request or receive any documents from Anthropic. There was no need, as Mr Heppner had saved the advice locally on his own device. Nonetheless, the court’s reasoning regarding the privacy policy made it clear that subpoenaing the AI company directly would have been a viable path. Indeed, this kind of document discovery is not merely a theoretical concern. Last year, DHS investigators obtained prompt-level data from OpenAI through a warrant in a criminal investigation. Furthermore, in copyright litigation between the New York Times and OpenAI, the court compelled the production of twenty million anonymised chat logs. It is clear that AI companies may therefore be forced to hand over stored user data during negotiations or under legal compulsion. You cannot assume that anything submitted into a publicly available AI is or will remain confidential. 

The fact that Mr Heppner was using a version of Claude lacking any confidentiality restrictions was clearly highly influential to the outcome of the case. These publicly available tools are different to the enterprise-grade versions, provided under conditions of confidentiality, with no training on user data and no data retention agreements in place. However, regardless of even these provisions, the saved outputs of AI tools may be a different matter. Caution must therefore be taken with the use of third-party software providers and software that may store your inputs, outputs and chat history, even when these are stored locally or provided under conditions of confidentiality. Documented opinions about the validity and potential infringement risk of patents without a clear client-attorney relationship are always fraught with risk, regardless of who or what generated them. 

Author: Rose Hughes

Rose Hughes

Rose is a biotech and pharmaceutical patent specialist with over a decade of experience in intellectual property. Rose is a Patent Director at Evolve, where she leverages our unique fractional in-house model to provide clients with deep patent law expertise combined with the strategic commercial oversight typically associated with senior in-house counsel.

With a PhD in Immunology from UCL, Rose applies her technical background to complex innovations in biologics, cell and gene therapies, and the rapidly emerging field of AI-assisted drug development. Previously, Rose held the role of Director, Patents at AstraZeneca, where she was responsible for global IP portfolios and IP strategy at every stage of the pharmaceutical pipeline, from platform development and on-market commercialisation to SPCs and patent term extensions.

A recognised thought leader in the field, Rose has been a regular contributor to IPKat since 2018, offering practical insights into European patent law developments. She is also a frequent speaker on the epi podcast, a guest lecturer for the Brunel University IP law Postgrad Certificate, and a contributing author to published books A User’s Guide to Intellectual Property in Life Sciences (2021) and Developments and Directions in Intellectual Property Law (2023).

Related insights...

Twisting strand of gold beads with a turquoise section on dark blue, Evolve biotechnology image
Twisting strand of gold beads with a turquoise section on dark blue, Evolve biotechnology image

AI for patent sequences: Avoiding costly sequence errors

  • 6th November 2026
A single wrong residue can mean a patent does not cover the product. Evolve’s AI Sequence Agents build ST.26 listings in code, check every residue, keep the claims covering the lead in line with the IP strategy from drafting to grant, and check the sequences in granted patents.
Grid of gold cubes with one turquoise cube lifted on dark blue, Evolve AI drug discovery image
Grid of gold cubes with one turquoise cube lifted on dark blue, Evolve AI drug discovery image

AI in the patent industry: Instant coffee Copilot

  • 4th November 2026
It is now abundantly clear that AI cannot be ignored by the patent industry. However, amongst the private practice firms, there still remains a divergence of approach, with many attorneys still not using AI in their day-to-day practice.
Ordered block of gold plates with three turquoise plates lifted out on dark blue, Evolve abstract article image
Ordered block of gold plates with three turquoise plates lifted out on dark blue, Evolve abstract article image

AI in the patent industry: The sneaky practice of prompt injection (and what to do about it)

  • 30th October 2026
As patent attorneys, we are by now all hopefully well versed in the confidentiality and hallucination risks of using AI. However, as AI tools are increasingly used to read, summarise and come to conclusions about third-party documents, there is another risk we need to think about: prompt injection. This is the sneaky practice of hiding…
Pyramid of gold spheres with a turquoise apex and pink equator line on dark blue, Evolve Franklin image
Pyramid of gold spheres with a turquoise apex and pink equator line on dark blue, Evolve Franklin image

Franklin: AI-powered publication review for pharma

  • 23rd October 2026
Publication screening is a time sink for pharma patent attorneys. Franklin quickly finds the undisclosed inventions in a new publication submission.
Turquoise sphere held in gold gyroscope rings with a pink edge line on dark blue, Evolve Albert image
Turquoise sphere held in gold gyroscope rings with a pink edge line on dark blue, Evolve Albert image

Albert – Construe: defining your claims before they are defined for you.

  • 25th September 2026
Albert – Construe is the latest addition to Evolve’s proprietary AI toolkit.  It construes a set of claims, sets out with supporting evidence what each unclear term means, highlights any inconsistencies caused by other disclosures within an application, and flags where amendments may have changed the scope of a claim term.
Ordered block of gold plates with three turquoise plates lifted out on dark blue, Evolve abstract article image
Ordered block of gold plates with three turquoise plates lifted out on dark blue, Evolve abstract article image

AI in the patent industry: Beware the MCP Trojan horse

  • 11th September 2026
As patent attorneys, we should all know by now not to put client confidential information into a non-enterprise version of an LLM. However, as the capabilities of AI tools become more complex, so too does the necessity of understanding what exactly they are doing and where our data goes, beyond the simple prompt.
Gold bar dissolving into turquoise fragments at its centre on dark blue, Evolve abstract article image
Gold bar dissolving into turquoise fragments at its centre on dark blue, Evolve abstract article image

AI in the patent industry: Bubble trouble and the affordability myth

  • 20th July 2026
Whenever we write about AI, responses have started to move away from talk about hallucination, confidentiality or quality. The new concern is one of economics, i.e. will the whole AI thing just become too expensive and are we putting ourselves at risk by outsourcing to AI.
Ordered block of gold plates with three turquoise plates lifted out on dark blue, Evolve abstract article image
Ordered block of gold plates with three turquoise plates lifted out on dark blue, Evolve abstract article image

Podcast: Staring into the AI abyss

  • 14th July 2026
INSIGHT epi – The podcast for European patent professionals
Gold band splitting into three branches at a turquoise junction on dark blue, Evolve abstract article image
Gold band splitting into three branches at a turquoise junction on dark blue, Evolve abstract article image

AI in the patent industry: The risks of AI shadow use

  • 8th July 2026
In many patent firms, permission to use AI tools is currently restricted to the most senior individuals. Whilst almost every firm seems to have a dedicated “AI task-force” these days to trial new software, this group is usually restricted to partners or senior associates, whilst trainees and more junior associates are denied access to AI…
Turquoise sphere held in gold gyroscope rings with a pink edge line on dark blue, Evolve Albert image
Turquoise sphere held in gold gyroscope rings with a pink edge line on dark blue, Evolve Albert image

Albert: AI-powered competitive intelligence and IP validity analysis for biotech & pharma

  • 23rd June 2026
Expert analysis based on deep industry expertise, delivered quickly and cost-effectively.
All Insights

evolve® is a trading entity of Evolve Intellectual Property Limited. Evolve Intellectual Property Limited is regulated by the Intellectual Property Regulation Board (IPReg). Details of the UK professional rules can be found on the IPReg website

registered address: 49 Greek Street, London, England, W1D 4EG

website out of house

© 2026 All Rights Reserved

Keep in touch

  • Subscribe
  • Contact us
  • Cookie Notice
  • Complaints Procedure
  • Privacy notice
  • Subscribe
  • Contact us
  • Cookie Notice
  • Complaints Procedure
  • Privacy notice